ZITHROMAX 4 Dosage And Administration

azithromycin dihydrate

(

4.1 Dosing Considerations

ZITHROMAX immediate-release oral formulations (tablets or oral suspension) are not bioequivalent and are not interchangeable with azithromycin sustained release due to a different pharmacokinetic profile.

Hepatic Impairment:

No dose adjustment of oral ZITHROMAX preparations is recommended for patients with mild to moderate hepatic impairment. Azithromycin has not been studied in patients with severe hepatic impairment. Since the liver is the principal route of elimination for azithromycin, the use of oral ZITHROMAX preparations should be undertaken with caution in patients with impaired hepatic function (see 7 WARNINGS AND PRECAUTIONS and 10 CLINICAL PHARMACOLOGY). Due to the lack of data, ZITHROMAX for Injection should be used with caution in patients with hepatic impairment.

Renal Impairment:

No dosage adjustment of oral ZITHROMAX preparations is recommended for subjects with GFR 10-80 mL/min. The mean AUC0-120 increased 35% in subjects with GFR 7 WARNINGS AND PRECAUTIONS and 10 CLINICAL PHARMACOLOGY).

Due to the lack of data, ZITHROMAX for Injection should be used with caution in patients with renal impairment (including patients on dialysis).

4.2 Recommended Dose and Dosage Adjustment

ZITHROMAX for ORAL THERAPY

ADULTS

DOSING in relation to FOOD:

TABLETS: ZITHROMAX Tablets can be taken with or without food.

UPPER AND LOWER RESPIRATORY INFECTIONS/ SKIN AND SKIN STRUCTURE INFECTIONS:

The recommended dose of ZITHROMAX for individuals 16 years of age or older in the treatment of mild to moderate acute bacterial exacerbations of chronic obstructive pulmonary disease due to the indicated organisms is: either 500 mg per day for 3 days or 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams.

The recommended dose of ZITHROMAX for the treatment of community-acquired pneumonia of mild severity, uncomplicated skin and skin structure infections, and for pharyngitis/tonsillitis (as second-line therapy) due to the indicated organisms is: 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams.

GENITOURINARY INFECTIONS:

The recommended dose of ZITHROMAX for the treatment of genital ulcer disease due to Haemophilus ducreyi (chancroid) and non-gonococcal urethritis and cervicitis due to C. trachomatis is: a single 1 gram (1000 mg) oral dose of ZITHROMAX. This dose can be administered as four 250 mg tablets.

The recommended dose of ZITHROMAX for the treatment of urethritis and cervicitis due to Neisseria gonorrhoeae is: a single 2 gram (2000 mg) dose of ZITHROMAX. This dose can be administered as eight 250 mg tablets.

FOR PREVENTION OF DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX (MAC) DISEASE:

The recommended dose of ZITHROMAX for the prevention of disseminated Mycobacterium avium complex (MAC) disease is 1200 mg (two 600 mg tablets) taken once weekly. This dose of ZITHROMAX may be continued with the approved dosage regimen of rifabutin.

CHILDREN

DOSING in relation to FOOD:

POWDER FOR ORAL SUSPENSION: ZITHROMAX Powder for Oral Suspension can be taken with or without food (see 10 CINICAL PHARMACOLOGY).

PEDIATRIC DOSING GUIDELINES:

The recommended total dose for children is 30 mg/kg for otitis media and community acquired pneumonia. For pharyngitis/tonsillitis, the recommended total dose is 60 mg/kg.

Indication1-Day3-Day5-Day
Acute Otitis Media30 mg/kg10 mg/kg/dayDay 1: 10 mg/kg
Day 2-5: 5 mg/kg
Pharyngitis/ Tonsillitis  12 mg/kg/day
Community-Acquired Pneumonia  Day 1: 10 mg/kg
Day 2-5: 5 mg/kg

ACUTE OTITIS MEDIA:

The recommended dose of ZITHROMAX oral suspension for the treatment of children with acute otitis media is 30 mg/kg given as a single dose (not to exceed 1500 mg) or 10 mg/kg once daily for 3 days (not to exceed 500 mg/day) or 10 mg/kg as a single dose on the first day (not to exceed 500 mg/day) followed by 5 mg/kg/day on days 2 through 5 (not to exceed 250 mg/day). (See chart #1, 2 and 3 respectively below).

The safety of re-dosing azithromycin in children who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, eight patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.

COMMUNITY-ACQUIRED PNEUMONIA:

The recommended dose of ZITHROMAX for oral suspension for the treatment of children with community-acquired pneumonia is 10 mg/kg as a single dose on the first day (not to exceed 500 mg/day) followed by 5 mg/kg on days 2 through 5 (not to exceed 250 mg/day). (See chart #3 below).

Effectiveness of the 3-day or 1-day regimen in children with community-acquired pneumonia has not been established.

PHARYNGITIS AND TONSILLITIS:

The recommended dose for children with pharyngitis and tonsillitis is 12 mg/kg once daily for 5 days (not to exceed 500 mg/day). (See chart #4 below).

PEDIATRIC DOSAGE GUIDELINES
BASED on BODY Weight

CHART #1
OTITIS MEDIA: (1-Day Regimen)*
Dosing Calculated on 30 mg/kg as a single dose
Age 6 months and above, see 7.1.3 Pediatrics
Weight200 mg/5 mL
Day 1
Total mL per
Treatment Course
Total mg per Treatment
Course
KgLbs.
5113.75 mL (3/4 tsp)3.75 mL150 mg
10227.5 mL (1 ½ tsp)7.5 mL300 mg
204415 mL (3 tsp)15 mL600 mg
306622.5 mL (4 ½ tsp)22.5 mL900 mg
408830 mL (6 tsp)30 mL1200 mg
50 and above110 and above37.5 mL (7 ½ tsp)37.5 mL1500 mg

*

Effectiveness of the 1-day regimen in children with community-acquired pneumonia has not been established.

CHART #2
OTITIS MEDIA: (3-Day Regimen)*
Dosing Calculated on 10 mg/kg/day
Age 6 months and above, see 7.1.3 Pediatrics
Weight100 mg/5 mL
Day 1-3
200 mg/5 mL
Day 1-3
Total mL per Treatment CourseTotal mg per Treatment Course
KgLbs.
5112.5 mL (1/2 tsp) 7.5 mL150 mg
10225 mL (1 tsp) 15 mL300 mg
2044 5 mL (1 tsp)15 mL600 mg
3066 7.5 mL (1 ½ tsp)22.5 mL900 mg
4088 10 mL (2 tsp)30 mL1200 mg
50 and above110 and above 12.5 mL (2 ½ tsp)37.5 mL1500 mg

*

Effectiveness of the 3-day regimen in children with community-acquired pneumonia has not been established.

CHART #3
ACUTE OTITIS MEDIA OR COMMUNITY-ACQUIRED PNEUMONIA
Age 6 months and above, see 7.1.3 Pediatrics
5-Day Regimen
Dosing Calculated on 10 mg/kg on Day 1 dose, followed by 5 mg/kg on Days 2 to 5
Weight100 mg/5 mL Suspension200 mg/5 mL SuspensionTotal mL per Treatment CourseTotal mg per Treatment Course
KglbsDay 1Days 2-5Day 1Days 2-5
5112.5 mL (½ tsp)1.25 mL (¼ tsp)   7.5 mL150 mg
10225 mL (1tsp)2.5 mL (½ tsp)  15 mL300 mg
2044  5 mL (1 tsp)2.5 mL (½ tsp)15 mL600 mg
3066  7.5 mL (1½ tsp)3.75 mL (¾ tsp)22.5 mL900 mg
4088  10 mL (2tsp)5 mL (1tsp)30 mL1200 mg
50 and above110 and above  12.5mL (2½ tsp)6.25 mL (1¼ tsp)37.5 mL1500 mg
CHART # 4
PHARYNGITIS AND TONSILLITIS: (5-Day Regimen)
(Age 2 years and above see 7.1.3 Pediatrics)
Dosing Calculated on 12 mg/kg once daily Days 1 to 5
Weight200 mg/5 mL SuspensionTotal mL per Treatment CourseTotal mg per Treatment Course
KgLbsDay 1-5
8182.5 mL (½ tsp)12.5 mL   500 mg
17375 mL (1tsp)25 mL1000 mg
25557.5 mL (1½ tsp)37.5 mL1500 mg
337310 mL (2 tsp)50 mL2000 mg
408812.5 mL (2 ½ tsp)62.5 mL2500 mg

ZITHROMAX for INTRAVENOUS INJECTION

ADULTS

ZITHROMAX for Injection must be reconstituted and diluted, as directed, and administered as an intravenous infusion over at least 60 minutes. Do not administer as an intravenous bolus or an intramuscular injection (see 7 WARNINGS AND PRECAUTIONS). Intravenous therapy should be followed by oral ZITHROMAX. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response.

The infusate concentration and rate of infusion for ZITHROMAX should be either 1 mg/mL over 3 hours, or 2 mg/mL over 1 hour.

COMMUNITY-ACQUIRED PNEUMONIA: in patients who require initial intravenous therapy:

The recommended dose is 500 mg I.V. as a single daily infusion for at least 2 days followed by oral therapy at 500 mg daily to complete a 7-10 day course of therapy.

PELVIC INFLAMMATORY DISEASE:

The recommended dose is 500 mg I.V. as a single daily infusion for at least 1 day followed by oral therapy at 250 mg daily to complete a 7-day course of therapy. Note: If anaerobic organisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with ZITHROMAX.

4.3 Reconstitution:

ZITHROMAX Powder for Oral Suspension:

Tap bottle to loosen powder. Add the directed volume of water. Shake well before each use. Oversized bottle provides shake space. Keep tightly closed. The table below indicates the volume of water to be used for reconstitution:

Amount of water to be addedNominal volume after reconstitution (azithromycin content)Azithromycin concentration after reconstitution
 9 mL (300 mg bottle)  15 mL (300 mg bottle)100 mg/5 mL
9 mL (600 mg bottle)15 mL (600 mg bottle)200 mg/5 mL
12 mL (900 mg bottle)22.5 mL (900 mg bottle)200 mg/5 mL

Use only the dosing device provided to measure the correct amount of suspension (see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING). The dosing device may need to be filled multiple times to provide the complete dose prescribed.  Rinse the device with water after the complete daily dose has been administered.

Following constitution, and for use with the oral syringe, the supplied plastic stopper should be inserted into the neck of the bottle then sealed with the original closure.

ZITHROMAX for Injection:

RECONSTITUTION OF ZITHROMAX FOR INJECTION
StrengthReconstitution SolutionVolume to be AddedApproximate Volume AvailableNominal Concentration
500 mgSterile Water for Injection4.8 mL5 mL100 mg/mL

Prepare the initial solution of ZITHROMAX for Injection by adding 4.8 mL of Sterile Water for Injection to the 500 mg vial. Shake the vial until all of the drug is dissolved. Since the vial is evacuated, it is recommended that a standard 5 mL (non-automated) syringe be used to ensure that the exact volume of 4.8 mL is dispensed. Each mL of reconstituted solution contains azithromycin dihydrate equivalent to 100 mg azithromycin. Reconstituted solution is stable for 24 hours when stored below 30°C. The reconstituted solution must be further diluted prior to administration.

Dilution of reconstituted solution: To provide azithromycin over a concentration range of 1.0 - 2.0 mg/mL, transfer 5 mL of the 100 mg/mL azithromycin solution into the appropriate amount of the following diluents:

Final Infusion Concentration (mg/mL)Amount of Diluent (mL)
1.0 mg/mL500 mL
2.0 mg/mL250 mL
Appropriate Diluents
0.9% Sodium Chloride Injection
5% Dextrose in Water for Injection
0.45% Sodium Chloride Injection
Lactated Ringer’s Injection
5% Dextrose in 0.45% Sodium Chloride Injection with 20 mEq Potassium Chloride
5% Dextrose in Lactated Ringer’s Injection
5% Dextrose in 0.3% Sodium Chloride Injection
5% Dextrose in 0.45% Sodium Chloride Injection
Normosol-M in 5% Dextrose

Diluted solutions prepared in this manner are stable for 24 hours at or below room temperature (30°C), or for 72 hours if stored under refrigeration (2-8°C). As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should be discarded.

Only limited data are available on the compatibility of ZITHROMAX for Injection with other intravenous substances, therefore additives or other medications should not be added to ZITHROMAX for Injection or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of ZITHROMAX for Injection with an infusion solution compatible with ZITHROMAX for Injection and with any other drug(s) administered via the common line. If ZITHROMAX for Injection is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each drug.

4.5 Missed Dose

In case of missed dose, patients should not double the next dose.

)

Find ZITHROMAX medical information:

Find ZITHROMAX medical information:

Our scientific content is evidence-based, scientifically balanced and non-promotional. It undergoes rigorous internal medical review and is updated regularly to reflect new information.

ZITHROMAX Quick Finder

Product Monograph
Download Product Monograph

Health Professional Information

4 Dosage And Administration

4.1 Dosing Considerations

ZITHROMAX immediate-release oral formulations (tablets or oral suspension) are not bioequivalent and are not interchangeable with azithromycin sustained release due to a different pharmacokinetic profile.

Hepatic Impairment:

No dose adjustment of oral ZITHROMAX preparations is recommended for patients with mild to moderate hepatic impairment. Azithromycin has not been studied in patients with severe hepatic impairment. Since the liver is the principal route of elimination for azithromycin, the use of oral ZITHROMAX preparations should be undertaken with caution in patients with impaired hepatic function (see 7 WARNINGS AND PRECAUTIONS and 10 CLINICAL PHARMACOLOGY). Due to the lack of data, ZITHROMAX for Injection should be used with caution in patients with hepatic impairment.

Renal Impairment:

No dosage adjustment of oral ZITHROMAX preparations is recommended for subjects with GFR 10-80 mL/min. The mean AUC0-120 increased 35% in subjects with GFR 7 WARNINGS AND PRECAUTIONS and 10 CLINICAL PHARMACOLOGY).

Due to the lack of data, ZITHROMAX for Injection should be used with caution in patients with renal impairment (including patients on dialysis).

4.2 Recommended Dose and Dosage Adjustment

ZITHROMAX for ORAL THERAPY

ADULTS

DOSING in relation to FOOD:

TABLETS: ZITHROMAX Tablets can be taken with or without food.

UPPER AND LOWER RESPIRATORY INFECTIONS/ SKIN AND SKIN STRUCTURE INFECTIONS:

The recommended dose of ZITHROMAX for individuals 16 years of age or older in the treatment of mild to moderate acute bacterial exacerbations of chronic obstructive pulmonary disease due to the indicated organisms is: either 500 mg per day for 3 days or 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams.

The recommended dose of ZITHROMAX for the treatment of community-acquired pneumonia of mild severity, uncomplicated skin and skin structure infections, and for pharyngitis/tonsillitis (as second-line therapy) due to the indicated organisms is: 500 mg as a single dose on the first day followed by 250 mg once daily on days 2 through 5 for a total dose of 1.5 grams.

GENITOURINARY INFECTIONS:

The recommended dose of ZITHROMAX for the treatment of genital ulcer disease due to Haemophilus ducreyi (chancroid) and non-gonococcal urethritis and cervicitis due to C. trachomatis is: a single 1 gram (1000 mg) oral dose of ZITHROMAX. This dose can be administered as four 250 mg tablets.

The recommended dose of ZITHROMAX for the treatment of urethritis and cervicitis due to Neisseria gonorrhoeae is: a single 2 gram (2000 mg) dose of ZITHROMAX. This dose can be administered as eight 250 mg tablets.

FOR PREVENTION OF DISSEMINATED MYCOBACTERIUM AVIUM COMPLEX (MAC) DISEASE:

The recommended dose of ZITHROMAX for the prevention of disseminated Mycobacterium avium complex (MAC) disease is 1200 mg (two 600 mg tablets) taken once weekly. This dose of ZITHROMAX may be continued with the approved dosage regimen of rifabutin.

CHILDREN

DOSING in relation to FOOD:

POWDER FOR ORAL SUSPENSION: ZITHROMAX Powder for Oral Suspension can be taken with or without food (see 10 CINICAL PHARMACOLOGY).

PEDIATRIC DOSING GUIDELINES:

The recommended total dose for children is 30 mg/kg for otitis media and community acquired pneumonia. For pharyngitis/tonsillitis, the recommended total dose is 60 mg/kg.

Indication1-Day3-Day5-Day
Acute Otitis Media30 mg/kg10 mg/kg/dayDay 1: 10 mg/kg
Day 2-5: 5 mg/kg
Pharyngitis/ Tonsillitis  12 mg/kg/day
Community-Acquired Pneumonia  Day 1: 10 mg/kg
Day 2-5: 5 mg/kg

ACUTE OTITIS MEDIA:

The recommended dose of ZITHROMAX oral suspension for the treatment of children with acute otitis media is 30 mg/kg given as a single dose (not to exceed 1500 mg) or 10 mg/kg once daily for 3 days (not to exceed 500 mg/day) or 10 mg/kg as a single dose on the first day (not to exceed 500 mg/day) followed by 5 mg/kg/day on days 2 through 5 (not to exceed 250 mg/day). (See chart #1, 2 and 3 respectively below).

The safety of re-dosing azithromycin in children who vomit after receiving 30 mg/kg as a single dose has not been established. In clinical studies involving 487 patients with acute otitis media given a single 30 mg/kg dose of azithromycin, eight patients who vomited within 30 minutes of dosing were re-dosed at the same total dose.

COMMUNITY-ACQUIRED PNEUMONIA:

The recommended dose of ZITHROMAX for oral suspension for the treatment of children with community-acquired pneumonia is 10 mg/kg as a single dose on the first day (not to exceed 500 mg/day) followed by 5 mg/kg on days 2 through 5 (not to exceed 250 mg/day). (See chart #3 below).

Effectiveness of the 3-day or 1-day regimen in children with community-acquired pneumonia has not been established.

PHARYNGITIS AND TONSILLITIS:

The recommended dose for children with pharyngitis and tonsillitis is 12 mg/kg once daily for 5 days (not to exceed 500 mg/day). (See chart #4 below).

PEDIATRIC DOSAGE GUIDELINES
BASED on BODY Weight

CHART #1
OTITIS MEDIA: (1-Day Regimen)*
Dosing Calculated on 30 mg/kg as a single dose
Age 6 months and above, see 7.1.3 Pediatrics
Weight200 mg/5 mL
Day 1
Total mL per
Treatment Course
Total mg per Treatment
Course
KgLbs.
5113.75 mL (3/4 tsp)3.75 mL150 mg
10227.5 mL (1 ½ tsp)7.5 mL300 mg
204415 mL (3 tsp)15 mL600 mg
306622.5 mL (4 ½ tsp)22.5 mL900 mg
408830 mL (6 tsp)30 mL1200 mg
50 and above110 and above37.5 mL (7 ½ tsp)37.5 mL1500 mg

*

Effectiveness of the 1-day regimen in children with community-acquired pneumonia has not been established.

CHART #2
OTITIS MEDIA: (3-Day Regimen)*
Dosing Calculated on 10 mg/kg/day
Age 6 months and above, see 7.1.3 Pediatrics
Weight100 mg/5 mL
Day 1-3
200 mg/5 mL
Day 1-3
Total mL per Treatment CourseTotal mg per Treatment Course
KgLbs.
5112.5 mL (1/2 tsp) 7.5 mL150 mg
10225 mL (1 tsp) 15 mL300 mg
2044 5 mL (1 tsp)15 mL600 mg
3066 7.5 mL (1 ½ tsp)22.5 mL900 mg
4088 10 mL (2 tsp)30 mL1200 mg
50 and above110 and above 12.5 mL (2 ½ tsp)37.5 mL1500 mg

*

Effectiveness of the 3-day regimen in children with community-acquired pneumonia has not been established.

CHART #3
ACUTE OTITIS MEDIA OR COMMUNITY-ACQUIRED PNEUMONIA
Age 6 months and above, see 7.1.3 Pediatrics
5-Day Regimen
Dosing Calculated on 10 mg/kg on Day 1 dose, followed by 5 mg/kg on Days 2 to 5
Weight100 mg/5 mL Suspension200 mg/5 mL SuspensionTotal mL per Treatment CourseTotal mg per Treatment Course
KglbsDay 1Days 2-5Day 1Days 2-5
5112.5 mL (½ tsp)1.25 mL (¼ tsp)   7.5 mL150 mg
10225 mL (1tsp)2.5 mL (½ tsp)  15 mL300 mg
2044  5 mL (1 tsp)2.5 mL (½ tsp)15 mL600 mg
3066  7.5 mL (1½ tsp)3.75 mL (¾ tsp)22.5 mL900 mg
4088  10 mL (2tsp)5 mL (1tsp)30 mL1200 mg
50 and above110 and above  12.5mL (2½ tsp)6.25 mL (1¼ tsp)37.5 mL1500 mg
CHART # 4
PHARYNGITIS AND TONSILLITIS: (5-Day Regimen)
(Age 2 years and above see 7.1.3 Pediatrics)
Dosing Calculated on 12 mg/kg once daily Days 1 to 5
Weight200 mg/5 mL SuspensionTotal mL per Treatment CourseTotal mg per Treatment Course
KgLbsDay 1-5
8182.5 mL (½ tsp)12.5 mL   500 mg
17375 mL (1tsp)25 mL1000 mg
25557.5 mL (1½ tsp)37.5 mL1500 mg
337310 mL (2 tsp)50 mL2000 mg
408812.5 mL (2 ½ tsp)62.5 mL2500 mg

ZITHROMAX for INTRAVENOUS INJECTION

ADULTS

ZITHROMAX for Injection must be reconstituted and diluted, as directed, and administered as an intravenous infusion over at least 60 minutes. Do not administer as an intravenous bolus or an intramuscular injection (see 7 WARNINGS AND PRECAUTIONS). Intravenous therapy should be followed by oral ZITHROMAX. The timing of the switch to oral therapy should be done at the discretion of the physician and in accordance with clinical response.

The infusate concentration and rate of infusion for ZITHROMAX should be either 1 mg/mL over 3 hours, or 2 mg/mL over 1 hour.

COMMUNITY-ACQUIRED PNEUMONIA: in patients who require initial intravenous therapy:

The recommended dose is 500 mg I.V. as a single daily infusion for at least 2 days followed by oral therapy at 500 mg daily to complete a 7-10 day course of therapy.

PELVIC INFLAMMATORY DISEASE:

The recommended dose is 500 mg I.V. as a single daily infusion for at least 1 day followed by oral therapy at 250 mg daily to complete a 7-day course of therapy. Note: If anaerobic organisms are suspected of contributing to the infection, an antimicrobial agent with anaerobic activity should be administered in combination with ZITHROMAX.

4.3 Reconstitution:

ZITHROMAX Powder for Oral Suspension:

Tap bottle to loosen powder. Add the directed volume of water. Shake well before each use. Oversized bottle provides shake space. Keep tightly closed. The table below indicates the volume of water to be used for reconstitution:

Amount of water to be addedNominal volume after reconstitution (azithromycin content)Azithromycin concentration after reconstitution
 9 mL (300 mg bottle)  15 mL (300 mg bottle)100 mg/5 mL
9 mL (600 mg bottle)15 mL (600 mg bottle)200 mg/5 mL
12 mL (900 mg bottle)22.5 mL (900 mg bottle)200 mg/5 mL

Use only the dosing device provided to measure the correct amount of suspension (see 6 DOSAGE FORMS, STRENGTHS, COMPOSITION AND PACKAGING). The dosing device may need to be filled multiple times to provide the complete dose prescribed.  Rinse the device with water after the complete daily dose has been administered.

Following constitution, and for use with the oral syringe, the supplied plastic stopper should be inserted into the neck of the bottle then sealed with the original closure.

ZITHROMAX for Injection:

RECONSTITUTION OF ZITHROMAX FOR INJECTION
StrengthReconstitution SolutionVolume to be AddedApproximate Volume AvailableNominal Concentration
500 mgSterile Water for Injection4.8 mL5 mL100 mg/mL

Prepare the initial solution of ZITHROMAX for Injection by adding 4.8 mL of Sterile Water for Injection to the 500 mg vial. Shake the vial until all of the drug is dissolved. Since the vial is evacuated, it is recommended that a standard 5 mL (non-automated) syringe be used to ensure that the exact volume of 4.8 mL is dispensed. Each mL of reconstituted solution contains azithromycin dihydrate equivalent to 100 mg azithromycin. Reconstituted solution is stable for 24 hours when stored below 30°C. The reconstituted solution must be further diluted prior to administration.

Dilution of reconstituted solution: To provide azithromycin over a concentration range of 1.0 - 2.0 mg/mL, transfer 5 mL of the 100 mg/mL azithromycin solution into the appropriate amount of the following diluents:

Final Infusion Concentration (mg/mL)Amount of Diluent (mL)
1.0 mg/mL500 mL
2.0 mg/mL250 mL
Appropriate Diluents
0.9% Sodium Chloride Injection
5% Dextrose in Water for Injection
0.45% Sodium Chloride Injection
Lactated Ringer’s Injection
5% Dextrose in 0.45% Sodium Chloride Injection with 20 mEq Potassium Chloride
5% Dextrose in Lactated Ringer’s Injection
5% Dextrose in 0.3% Sodium Chloride Injection
5% Dextrose in 0.45% Sodium Chloride Injection
Normosol-M in 5% Dextrose

Diluted solutions prepared in this manner are stable for 24 hours at or below room temperature (30°C), or for 72 hours if stored under refrigeration (2-8°C). As with all parenteral drug products, intravenous admixtures should be inspected visually for clarity, particulate matter, precipitate, discoloration and leakage prior to administration, whenever solution and container permit. Solutions showing haziness, particulate matter, precipitate, discoloration or leakage should be discarded.

Only limited data are available on the compatibility of ZITHROMAX for Injection with other intravenous substances, therefore additives or other medications should not be added to ZITHROMAX for Injection or infused simultaneously through the same intravenous line. If the same intravenous line is used for sequential infusion of several different drugs, the line should be flushed before and after infusion of ZITHROMAX for Injection with an infusion solution compatible with ZITHROMAX for Injection and with any other drug(s) administered via the common line. If ZITHROMAX for Injection is to be given concomitantly with another drug, each drug should be given separately in accordance with the recommended dosage and route of administration for each drug.

4.5 Missed Dose

In case of missed dose, patients should not double the next dose.

Resources

Didn’t find what you were looking for? 

Contact us

Call 1-800-463-6001*

*Contact Medical Information. 9AM-5PM ET Monday to Friday; excluding holidays.

Medical Inquiry

Submit a medical question for Pfizer prescription products.

Report Adverse Event

Pfizer Safety

Contact Pfizer Safety to report an adverse event, side effect or concern about the quality of a Pfizer product: 1 866 723-7111.

To report an adverse event related to COMIRNATY, and you are not part of a clinical trial* for this product, click the link below to submit your information:

Pfizer Safety Reporting Site

*If you are involved in a clinical trial for this product, adverse events should be reported to your coordinating study site.

Canada Vigilance Program 

You may also contact the Canada Vigilance Program directly to report adverse events or product quality concerns at 1-866-234-2345 or www.healthcanada.gc.ca/medeffect